Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 19;72(3):225-228.
doi: 10.1093/occmed/kqab164.

Underascertainment of COVID-19 cases among first responders: a seroepidemiological study

I Backhaus  1 , D Hermsen  2 , J Timm  3 , F Boege  2 , N Lübke  3 , K Göbels  4 , D von der Lieth  5 , N Dragano  1
Affiliations

Underascertainment of COVID-19 cases among first responders: a seroepidemiological study

I Backhaus et al. Occup Med (Lond). .

Abstract

Background: Providing frontline support places first responders at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Aims: This study was aimed to determine the anti-SARS-CoV-2 seroprevalence in a cohort of first responders (i.e. firefighters/paramedics), to detect the underascertainment rate and to assess risk factors associated with seropositivity.

Methods: We conducted a serological survey among 745 first responders in Germany during 27 November and 4 December 2020 to determine the anti-SARS-CoV-2 seroprevalence using Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, Mannheim, Germany). As part of the examination, participants were asked to provide information on coronavirus disease 2019 (COVID-19)-like-symptoms, information on sociodemographic characteristics and workplace risk factors for a SARS-CoV-2 infection and any prior COVID-19 infection. Descriptive statistics and logistic regression analysis were performed and seroprevalence estimates were adjusted for test sensitivity and specificity.

Results: The test-adjusted seroprevalence was 4% (95% CI 3.1-6.2) and the underascertainment rate was 2.3. Of those tested SARS-CoV-2 antibody positive, 41% were aware that they had been infected in the past. Seropositivity was elevated among paramedics who worked in the emergency rescue team providing first level of pre-hospital emergency care (6% [95% CI 3.4-8.6]) and those directly exposed to a COVID-19 case (5% [95% CI 3.5-8.1]). Overall, the seroprevalence and the underascertainment rate were higher among first responders than among the general population.

Conclusions: The high seroprevalence and underascertainment rate highlight the need to mitigate potential transmission within and between first responders and patients. Workplace control measures such as increased and regular COVID-19-testing and the prompt vaccination of all personnel are necessary.

Keywords: COVID-19; SARS-CoV-2; firefighters; infection risk; occupational medicine; paramedics; seroprevalence.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: a key factor in containing risk of COVID-19 infection. PLoS One 2020;15:e0232452. - PMC - PubMed
    1. Steensels D, Oris E, Coninx L et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. J Am Med Assoc 2020;324: 195–197. - PMC - PubMed
    1. Sami S, Akinbami LJ, Petersen LR et al. Prevalence of SARS-CoV-2 antibodies in first responders and public safety personnel, New York City, New York, USA, May–July 2020. Emerg Infect Dis 2021;27: 796–804. - PMC - PubMed
    1. Niu J, Rodriguez JA, Sareli C, Goldman J, Puga M, Eckardt PA. COVID-19 infection among first responders in Broward County, Florida, March–April 2020. J Public Health (Oxf) 2020;43:450–454. doi: 10.1093/pubmed/fdaa231. - DOI - PMC - PubMed
    1. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Eurosurveillance 2020;25:2001285. - PMC - PubMed

Substances